 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || Cantabell (amlodipine/candesartan cilexetil) / Chong Kun Dang
PK/PD data, Journal: Pharmacokinetic Comparison of a Fixed-Dose Combination of Candesartan Cilexetil/Amlodipine/Atorvastatin Versus Co-administration of Individual Formulations in Healthy Participants. (Pubmed Central) - May 21, 2024
P1
The Cmax and AUClast values of candesartan cilexetil/amlodipine/atorvastatin 16/10/40
- ||| Cantabell (amlodipine/candesartan cilexetil) / Chong Kun Dang, CKD-333 / Chong Kun Dang
New P1 trial: A Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of CKD-333 or Co-administration of CKD-333 and D085 in Healthy Volunteers (clinicaltrials.gov) - Nov 12, 2020
P1, N=51, Not yet recruiting, Sponsor: Chong Kun Dang Pharmaceutical
- ||| CKD-333 / Chong Kun Dang
New P1 trial: Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-333 Low Dose in Healthy Volunteers (clinicaltrials.gov) - Nov 1, 2020
P1, N=51, Not yet recruiting, Sponsor: Chong Kun Dang Pharmaceutical
- ||||| Cantabell (amlodipine/candesartan cilexetil) / Chong Kun Dang
Trial completion, Combination therapy, Monotherapy: Trial to Evaluate the Efficacy and Safety of a Combination Therapy of Candesartan and Amlodipine Versus Candesartan Monotherapy in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy (clinicaltrials.gov) - Aug 25, 2020
P3, N=135, Completed, Sponsor: Chong Kun Dang Pharmaceutical
The Cmax and AUClast values of candesartan cilexetil/amlodipine/atorvastatin 16/10/40 Recruiting --> Completed
- |||| Cantabell (amlodipine/candesartan cilexetil) / Chong Kun Dang
New P4 trial, Monotherapy, Head-to-Head: A Clinical Trial to Evaluate the Blood Pressure Lowering Effect of a Candemore Plus Tab Versus Cantabell Tab in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy (clinicaltrials.gov) - Aug 20, 2020
P4, N=132, Completed, Sponsor: Chong Kun Dang Pharmaceutical
- ||| Cantabell (amlodipine/candesartan cilexetil) / Chong Kun Dang, CKD-333 / Chong Kun Dang
New P1 trial: Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers (clinicaltrials.gov) - Jul 20, 2020
P1, N=51, Not yet recruiting, Sponsor: Chong Kun Dang Pharmaceutical
- || CKD-333 / Chong Kun Dang
Trial completion: Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of CKD-333 in Healthy Volunteers (clinicaltrials.gov) - Jan 29, 2020
P1, N=24, Completed, Sponsor: Chong Kun Dang Pharmaceutical
Recruiting --> Completed Not yet recruiting --> Completed
- | Cantabell (amlodipine/candesartan cilexetil) / Chong Kun Dang
Trial completion, Trial completion date, Trial primary completion date, Combination therapy: Clinical Trial to Evaluate the Efficacy and Safety of CKD-333 Tablet (clinicaltrials.gov) - Jul 24, 2019
P3, N=154, Completed, Sponsor: Chong Kun Dang Pharmaceutical
Not yet recruiting --> Completed Recruiting --> Completed | Trial completion date: Nov 2019 --> Jul 2019 | Trial primary completion date: Nov 2019 --> Jul 2019
- | CKD-333 / Chong Kun Dang
New P1 trial: Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of CKD-333 in Healthy Volunteers (clinicaltrials.gov) - Jul 14, 2019
P1, N=24, Not yet recruiting, Sponsor: Chong Kun Dang Pharmaceutical
- || Cantabell (amlodipine/candesartan cilexetil) / Chong Kun Dang, CKD-333 / Chong Kun Dang
New P1 trial: Compare the Pharmacokinetics and Safety of CKD-333 With Co-administration CKD-330 and D090 in Healthy Male Adults (clinicaltrials.gov) - Feb 21, 2019
P1, N=36, Not yet recruiting, Sponsor: Chong Kun Dang Pharmaceutical
- | Cantabell (amlodipine/candesartan cilexetil) / Chong Kun Dang, CKD-333 / Chong Kun Dang
Trial completion: Pharmacokinetics and Safety Profile of CKD-333 (clinicaltrials.gov) - Oct 31, 2018
P1, N=37, Completed, Sponsor: Chong Kun Dang Pharmaceutical
Recruiting --> Completed | Trial completion date: Nov 2019 --> Jul 2019 | Trial primary completion date: Nov 2019 --> Jul 2019 Recruiting --> Completed
- | Cantabell (amlodipine/candesartan cilexetil) / Chong Kun Dang, CKD-333 / Chong Kun Dang
New P1 trial: Pharmacokinetics and Safety Profile of CKD-333 (clinicaltrials.gov) - Sep 5, 2018
P1, N=36, Recruiting, Sponsor: Chong Kun Dang Pharmaceutical
- | Cantabell (amlodipine/candesartan cilexetil) / Chong Kun Dang
New P3 trial, Combination therapy: Clinical Trial to Evaluate the Efficacy and Safety of CKD-333 Tablet (clinicaltrials.gov) - Jul 16, 2018
P3, N=150, Recruiting, Sponsor: Chong Kun Dang Pharmaceutical
- ||| Cantabell (amlodipine/candesartan cilexetil) / Chong Kun Dang
Trial completion: Pharmacokinetic Drug-drug Interaction of CKD-330 and D086 (clinicaltrials.gov) - Jul 21, 2017
P1, N=83, Completed, Sponsor: Chong Kun Dang Pharmaceutical
Recruiting --> Completed Recruiting --> Completed
- ||| Cantabell (amlodipine/candesartan cilexetil) / Chong Kun Dang
New P1 trial: Pharmacokinetic Drug-drug Interaction of CKD-330 and D086 (clinicaltrials.gov) - Jan 11, 2017
P1, N=80, Recruiting, Sponsor: Chong Kun Dang Pharmaceutical
- ||||||| Cantabell (amlodipine/candesartan cilexetil) / Chong Kun Dang
Trial completion, Monotherapy: CKD-330 Phase 3 Trial in Amlodipine Non-responder (clinicaltrials.gov) - Oct 6, 2016
P3, N=160, Completed, Sponsor: Chong Kun Dang Pharmaceutical
Recruiting --> Completed Active, not recruiting --> Completed
- ||||| Cantabell (amlodipine/candesartan cilexetil) / Chong Kun Dang
Enrollment closed, Trial primary completion date, Monotherapy: CKD-330 Phase 3 Trial in Amlodipine Non-responder (clinicaltrials.gov) - Jul 18, 2016
P3, N=160, Active, not recruiting, Sponsor: Chong Kun Dang Pharmaceutical
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Aug 2016
- | Cantabell (amlodipine/candesartan cilexetil) / Chong Kun Dang
New P1 trial: Bioequivalence Study (Candesartan 16 mg and Amlodipine 5 mg) - B (clinicaltrials.gov) - Jun 23, 2016
P1, N=32, Completed, Sponsor: Chong Kun Dang Pharmaceutical
- | Cantabell (amlodipine/candesartan cilexetil) / Chong Kun Dang
New P1 trial: Bioequivalence Study (Candesartan 16 mg and Amlodipine 5 mg) - A (clinicaltrials.gov) - Jun 16, 2016
P1, N=32, Completed, Sponsor: Chong Kun Dang Pharmaceutical
- |||||| Cantabell (amlodipine/candesartan cilexetil) / Chong Kun Dang
Enrollment open, Trial primary completion date, Monotherapy: CKD-330 Phase 3 Trial in Amlodipine Non-responder (clinicaltrials.gov) - Apr 23, 2016
P3, N=160, Recruiting, Sponsor: Chong Kun Dang Pharmaceutical
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Aug 2016 Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2016 --> Dec 2016
- |||||||||| Cantabell (amlodipine/candesartan cilexetil) / Chong Kun Dang
New P3 trial, Combination therapy, Monotherapy: Trial to Evaluate the Efficacy and Safety of a Combination Therapy of Candesartan and Amlodipine Versus Candesartan Monotherapy in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy (clinicaltrials.gov) - Jan 11, 2016
P3, N=135, Recruiting, Sponsor: Chong Kun Dang Pharmaceutical
- ||| Cantabell (amlodipine/candesartan cilexetil) / Chong Kun Dang
Trial completion: Study to Compare the Safety and Pharmacokinetics of CKD-330 8/5mg With Coadministration of the Two Separate Drugs (clinicaltrials.gov) - Dec 5, 2015
P1, N=53, Completed, Sponsor: Chong Kun Dang Pharmaceutical
Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2016 --> Dec 2016 Active, not recruiting --> Completed
- |||||||||| Cantabell (amlodipine/candesartan cilexetil) / Chong Kun Dang
New P3 trial, Monotherapy: CKD-330 Phase 3 Trial in Amlodipine Non-responder (clinicaltrials.gov) - Oct 26, 2015
P3, N=160, Not yet recruiting, Sponsor: Chong Kun Dang Pharmaceutical
- ||| Cantabell (amlodipine/candesartan cilexetil) / Chong Kun Dang
New P1 trial: Study to Compare the Safety and Pharmacokinetics of CKD-330 8/5mg With Coadministration of the Two Separate Drugs (clinicaltrials.gov) - Sep 14, 2015
P1, N=53, Active, not recruiting, Sponsor: Chong Kun Dang Pharmaceutical
- || Cantabell (amlodipine/candesartan cilexetil) / Chong Kun Dang
Trial primary completion date: A Dose Selection Trial of CKD-330 in Patients With Essential Hypertension (clinicaltrials.gov) - Apr 15, 2015
P2, N=456, Recruiting, Sponsor: Chong Kun Dang Pharmaceutical
Active, not recruiting --> Completed Trial primary completion date: Jan 2015 --> Apr 2015
- | Cantabell (amlodipine/candesartan cilexetil) / Chong Kun Dang
Trial completion: Bioequivalence Study (Candesartan 8 mg and Amlodipine 5 mg) (clinicaltrials.gov) - Dec 5, 2014
P1, N=32, Completed, Sponsor: Chong Kun Dang Pharmaceutical
Trial primary completion date: Jan 2015 --> Apr 2015 Recruiting --> Completed
- | Cantabell (amlodipine/candesartan cilexetil) / Chong Kun Dang
Trial completion, Monotherapy: CKD-330 Drug-Drug Interaction Study (Candesartan) (clinicaltrials.gov) - Sep 4, 2014
P1, N=24, Completed, Sponsor: Chong Kun Dang Pharmaceutical
Recruiting --> Completed Not yet recruiting --> Completed
- | Cantabell (amlodipine/candesartan cilexetil) / Chong Kun Dang
Trial completion, Monotherapy: CKD-330 Drug-Drug Interaction Study (Amlodipine) (clinicaltrials.gov) - Aug 15, 2014
P1, N=24, Completed, Sponsor: Chong Kun Dang Pharmaceutical
Not yet recruiting --> Completed Not yet recruiting --> Completed
- ||||| Cantabell (amlodipine/candesartan cilexetil) / Chong Kun Dang
New P2 trial: A Dose Selection Trial of CKD-330 in Patients With Essential Hypertension (clinicaltrials.gov) - Aug 1, 2014
P2, N=456, Recruiting, Sponsor: Chong Kun Dang Pharmaceutical
- | Cantabell (amlodipine/candesartan cilexetil) / Chong Kun Dang
New P1 trial: Bioequivalence Study (Candesartan 8 mg and Amlodipine 5 mg) (clinicaltrials.gov) - Jul 12, 2014
P1, N=32, Recruiting, Sponsor: Chong Kun Dang Pharmaceutical
- | Cantabell (amlodipine/candesartan cilexetil) / Chong Kun Dang
New P1 trial, Monotherapy: CKD-330 Drug-Drug Interaction Study (Amlodipine) (clinicaltrials.gov) - Feb 13, 2014
P1, N=24, Not yet recruiting, Sponsor: Chong Kun Dang Pharmaceutical
- | Cantabell (amlodipine/candesartan cilexetil) / Chong Kun Dang
New P1 trial, Monotherapy: CKD-330 Drug-Drug Interaction Study (Candesartan) (clinicaltrials.gov) - Feb 13, 2014
P1, N=24, Not yet recruiting, Sponsor: Chong Kun Dang Pharmaceutical